| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nicholas D McKinnon, Alvi Azad, Brian M Waters, Kaustubh G Josh. Clozapine-induced bowel infarction: a case report. Psychiatry (Edgmont (Pa. : Township)). vol 6. issue 3. 2011-11-10. PMID:19724752. |
resistant schizophrenia is often treated with clozapine after other conventional atypical antipsychotics have failed or have resulted in intolerable side effects. |
2011-11-10 |
2023-08-12 |
Not clear |
| Shankar Srinivas Kuchibatla, Sofia Akram Cheema, Kripa S Chakravarthy, Hany George El Saye. A case report of neuroleptic malignant syndrome. BMJ case reports. vol 2009. 2011-11-10. PMID:21686818. |
a 32-year-old male patient with a history of treatment resistant paranoid schizophrenia developed neuroleptic malignant syndrome (nms) during changeover of his antipsychotic medication from zuclopenthixol depot to clozapine. |
2011-11-10 |
2023-08-12 |
Not clear |
| Shi Hyun Kang, Jong Il Lee, An Kee Chang, Yeon Ho Joo, Chang Yoon Kim, Seong Yoon Ki. Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine. Psychiatry investigation. vol 8. issue 3. 2011-11-10. PMID:21994515. |
genetic polymorphisms in the htr2c and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. |
2011-11-10 |
2023-08-12 |
Not clear |
| Shi Hyun Kang, Jong Il Lee, An Kee Chang, Yeon Ho Joo, Chang Yoon Kim, Seong Yoon Ki. Genetic Polymorphisms in the HTR2C and Peroxisome Proliferator-Activated Receptors Are Not Associated with Metabolic Syndrome in Patients with Schizophrenia Taking Clozapine. Psychiatry investigation. vol 8. issue 3. 2011-11-10. PMID:21994515. |
in this cross-sectional study, we investigated whether htr2c-759c/t, htr2c-697g/c, pparα v227a, and pparγ 161c/t genotypes were associated with metabolic syndrome (mets) in patients with schizophrenia taking clozapine. |
2011-11-10 |
2023-08-12 |
Not clear |
| N Manjunatha, G S Ram Kumar, R Vidyendaran, K Muralidharan, J P Joh. Delayed onset, protracted delirium and aspiration pneumonitis associated with a combination of clozapine and electroconvulsive therapy. Indian journal of psychological medicine. vol 33. issue 1. 2011-11-10. PMID:22021960. |
few studies reported the efficacy and safety in combination of clozapine and electroconvulsive therapy (ect) in schizophrenia; systematic studies are lacking. |
2011-11-10 |
2023-08-12 |
Not clear |
| Johan Fernø, Luis Varela, Silje Skrede, María Jesús Vázquez, Rubén Nogueiras, Carlos Diéguez, Antonio Vidal-Puig, Vidar M Steen, Miguel Lópe. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PloS one. vol 6. issue 6. 2011-11-02. PMID:21695181. |
the success of antipsychotic drug treatment in patients with schizophrenia is limited by the propensity of these drugs to induce hyperphagia, weight gain and other metabolic disturbances, particularly evident for olanzapine and clozapine. |
2011-11-02 |
2023-08-12 |
rat |
| Eromona Whiskey, Olubanke Olofinjana, David Taylo. The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study. Journal of psychopharmacology (Oxford, England). vol 25. issue 6. 2011-09-28. PMID:20305043. |
clozapine is the treatment of choice in refractory schizophrenia. |
2011-09-28 |
2023-08-12 |
Not clear |
| Marisa Möller, Jan L Du Preez, Robin Emsley, Brian H Harve. Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 21. issue 6. 2011-09-28. PMID:20965701. |
behavioral changes evoked by sir are associated with cortico-striatal oxidative stress that is reversed by clozapine treatment, providing novel insight into the neurobiology and treatment of schizophrenia. |
2011-09-28 |
2023-08-12 |
rat |
| Ana Paula Werneck, Jaime Cecilio Hallak, Eduardo Nakano, Helio Elki. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry research. vol 188. issue 3. 2011-09-27. PMID:21596442. |
time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. |
2011-09-27 |
2023-08-12 |
Not clear |
| Ana Paula Werneck, Jaime Cecilio Hallak, Eduardo Nakano, Helio Elki. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry research. vol 188. issue 3. 2011-09-27. PMID:21596442. |
in this study, the hypothesis that clozapine and some second generation antipsychotics (sga) were superior to first generation antipsychotics (fga) in preventing rehospitalization of patients with schizophrenia discharged from a university hospital in brazil was tested. |
2011-09-27 |
2023-08-12 |
Not clear |
| Ana Paula Werneck, Jaime Cecilio Hallak, Eduardo Nakano, Helio Elki. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry research. vol 188. issue 3. 2011-09-27. PMID:21596442. |
a retrospective observational study was conducted designed to evaluate time to rehospitalization of patients with schizophrenia discharged on a regimen of oral fga, depot fga, risperidone, olanzapine and amisulpride, other sga, or clozapine, during a three-year follow-up period. |
2011-09-27 |
2023-08-12 |
Not clear |
| Alessandro De Risio, Angelo Pancheri, Giovanna Simonetti, Diana Giannarelli, Luciana Stefanutto, Bruno Gentil. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 4. 2011-09-13. PMID:21447367. |
in this retrospective case series, we investigated the change in bprs scores and metabolic features like bmi, fasting glucose, total and ldl cholesterol, triglycerides, functional outcome honos rome and psp scores after aripiprazole augmentation in 16 persons with treatment-resistant schizophrenia who were already treated with clozapine. |
2011-09-13 |
2023-08-12 |
Not clear |
| Rakesh Karmacharya, Spencer K Lynn, Sarah Demarco, Angelica Ortiz, Xin Wang, Miriam Y Lundy, Zhihua Xie, Bruce M Cohen, Gregory M Miller, Edgar A Buttne. Behavioral effects of clozapine: involvement of trace amine pathways in C. elegans and M. musculus. Brain research. vol 1393. 2011-09-01. PMID:21529784. |
clozapine is an antipsychotic medication with superior efficacy in treatment refractory schizophrenia. |
2011-09-01 |
2023-08-12 |
mouse |
| A J E Visscher, D Cohe. [Peri-orbital oedema and therapy-resistant hypertension: unusual side-effects of clozapine]. Tijdschrift voor psychiatrie. vol 53. issue 8. 2011-09-01. PMID:21845558. |
a 49-year-old male, known to have been suffering from paranoid schizophrenia for 10 years, was treated twice with clozapine. |
2011-09-01 |
2023-08-12 |
Not clear |
| Dinora F González-Esquivel, Nelly Castro, Jesús Ramírez-Bermúdez, Verónica Custodio, Susana Rojas-Tomé, Rafael Castro-Román, Helgi Jung-Coo. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients. Arzneimittel-Forschung. vol 61. issue 6. 2011-08-30. PMID:21827043. |
plasma levels of clozapine and norclozapine in mexican schizophrenia patients. |
2011-08-30 |
2023-08-12 |
Not clear |
| Corrado Barbui, Simone Accordini, Michela Nosè, Scott Stroup, Marianna Purgato, Francesca Girlanda, Eleonora Esposito, Antonio Veronese, Michele Tansella, Andrea Ciprian. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21508849. |
aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. |
2011-08-29 |
2023-08-12 |
Not clear |
| Corrado Barbui, Simone Accordini, Michela Nosè, Scott Stroup, Marianna Purgato, Francesca Girlanda, Eleonora Esposito, Antonio Veronese, Michele Tansella, Andrea Ciprian. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21508849. |
this multisite study was conducted to compare the efficacy and tolerability of combination treatment with clozapine plus aripiprazole versus combination treatment with clozapine plus haloperidol in patients with schizophrenia who do not have an optimal response to clozapine. |
2011-08-29 |
2023-08-12 |
Not clear |
| Corrado Barbui, Simone Accordini, Michela Nosè, Scott Stroup, Marianna Purgato, Francesca Girlanda, Eleonora Esposito, Antonio Veronese, Michele Tansella, Andrea Ciprian. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. Journal of clinical psychopharmacology. vol 31. issue 3. 2011-08-29. PMID:21508849. |
these results suggest that augmentation of clozapine with aripiprazole offers no benefit with regard to treatment withdrawal and overall symptoms in schizophrenia compared with augmentation with haloperidol. |
2011-08-29 |
2023-08-12 |
Not clear |
| Renan P Souza, Herbert Y Meltzer, Jeffrey A Lieberman, Bernard Le Foll, James L Kenned. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Human psychopharmacology. vol 25. issue 7-8. 2011-08-25. PMID:20860064. |
we genotyped four variants in 140 schizophrenia patients assessed prospectively for clozapine response after 6 months. |
2011-08-25 |
2023-08-12 |
Not clear |
| M R A Muscatello, A Bruno, G Pandolfo, U Micò, P M Bellinghieri, G Scimeca, M Cacciola, D Campolo, S Settineri, R Zoccal. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Journal of psychopharmacology (Oxford, England). vol 25. issue 5. 2011-08-12. PMID:20615930. |
topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. |
2011-08-12 |
2023-08-12 |
Not clear |